

April 25, 2019

AURUS Synthesis

Contract Development & Manufacturing Services

То	То
The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001	The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051
Code: 540222	Code: LAURUSLABS

Dear Sirs,

Sub: Board Meeting

Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of the Company will be held on Thursday, May 02, 2019, *inter-alia*, to consider and approve the Audited Financial Results of the Company for the Financial Year ended March 31, 2019 and to recommend Dividend, if any, on Equity Shares for the year ended 31st March, 2019.

Further, the Company's trading window for dealing in securities by the Directors and Designated Persons has been closed from Thursday, 4th April 2019 as already intimated on April 04, 2019, and shall continue to remain closed till Saturday, 4th May 2019 (both days inclusive).

This is for your information and records.

Thanking you,

Yours sincerely, For Laurus Labs Limited

JRUS Generics

Active Pharmaceutical Ingredients & Intermediates

G. Venkateswar Reddy Company Secretary



Registered Office : Plot No:21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam - 531021, Andhra Pradesh, India. CIN : L24239AP2005PLC047518 T +91 891 3061222 F +91 891 3061270 E info@lauruslabs.com W lauruslabs.com

AURUS Ingredients

Specialty Ingredients for Nutraceutical & Allied Industry